Zydus gets USFDA nod to treat pulmonary arterial hypertension

March 29, 2019 | Friday | News

The company has received the final approval from the USFDA to market Ambrisentan Tablets USP (US RLD – Letairis Tablets), 5 mg and 10 mg.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies

The company has received the final approval from the USFDA to market Ambrisentan Tablets USP (US RLD – Letairis Tablets), 5 mg and 10 mg.

It is used to treat high blood pressure in the lungs (pulmonary arterial hypertension) and will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

The US sales of Ambrisentan Tablets USP stood at $ 943 million in 2018. The group now has 258 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.